chapter  8
Utilization of Genomic Signatures for Personalized Treatment of Breast Cancer
ByP. Kelly Marcom, Carey K. Anders, Geoffrey S. Ginsburg
Pages 16

The challenge of personalized cancer treatment lies in matching the most effective

therapy to the characteristics of an individual patient’s tumor. The selection

of therapy for both early-and late-stage breast cancer, as is the case for most

cancer therapy, is still largely empiric and guided by large, population-based,

randomized clinical trials. Althoughwidely adopted, this approach is inadequate for

the selection of individualized chemotherapy regimens. Estimates of benefit are

extrapolations from the effects observed in these large trials and are not necessarily

applicable to individual patients.